Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.44 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5893908 | 0.94 | PTGS2 (0.49) | ENPP2PTGS2NR1H4 | |
| SCHEMBL7089391 | 0.85 | PTGS2 (0.44) | PTGS2TRPA1ALDH1A1TSHR | |
| SCHEMBL1738692 | 0.82 | ENPP2 (0.46) | ENPP2PTGS2KCNJ1KCNH2CA2 | |
| SCHEMBL13231429 | 0.80 | ENPP2 (0.54) | ENPP2PTGS2CA2ALDH1A1 | |
| SCHEMBL1148233 | 0.80 | HTR6 (0.47) | KCNH2CA2TRPA1ALDH1A1TSHR | |
| SCHEMBL18552646 | 0.80 | TRPA1 (0.43) | CA2TRPA1ALDH1A1TSHR | |
| SCHEMBL1939488 | 0.79 | PSIP1 (0.63) | CA2TRPA1ALDH1A1TSHR | |
| SCHEMBL2376239 | 0.79 | ENPP2 (0.72) | ENPP2PTGS2 | |
| SCHEMBL16443971 | 0.79 | CA2 (0.47) | ENPP2PTGS2KCNJ1KCNH2CA2 | |
| SCHEMBL172035 | 0.78 | CA2 (0.64) | ENPP2PTGS2CA2ALDH1A1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 762 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118763273-A | Sulfonyl deep eutectic polymer electrolyte and preparation and application thereof | 青岛赛锂达储能产业技术研究院有限公司 | 2024-10-11 | — | — | CN | claimed |
| US-20230061859-A1 | PYRIDO[2,3-D]PYRIMIDINE HIV-1 REVERSE TRANSCRIPTASE INHIBITOR WB3, PREPARATION METHOD AND APPLICATION THEREOF | SHAN DONG UNIVERSITY (CN) | 2023-03-02 | — | — | US | claimed |
| CN-111205287-B | Pyrido [2,3-d ] pyrimidine HIV-1 reverse transcriptase inhibitor and preparation method and application thereof | 山东大学 | 2021-03-30 | — | — | CN | claimed |
| CN-111205287-A | Pyrido [2,3-d ] pyrimidine HIV-1 reverse transcriptase inhibitor and preparation method and application thereof | 山东大学 | 2020-05-29 | — | — | CN | claimed |
| US-10590145-B2 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | SHANDONG UNIVERSITY (CN) | 2020-03-17 | — | — | US | claimed |
| US-20200031844-A1 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | SHANDONG UNIVERSITY (CN) | 2020-01-30 | — | — | US | claimed |
| CN-108727295-A | A kind of 2- (3- aminophenyls)-benzothiazole derivant and its preparation method and application | 济南大学 | 2018-11-02 | — | — | CN | claimed |
| EP-4692085-A2 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20260035361-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | SHANGHAI DEGRON BIOMEDICAL TECH CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| EP-4041388-B1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025229046-A1 | SUBSTITUTED HYDROQUINOLINES FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME | MOLIUS SAGLIK TEKNOLOJILERI ANONIM SIRKETI (TR) | 2025-11-06 | — | — | WO | disclosed |
| EP-4626880-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | Shanghai Degron Biomedical Technology Co., Ltd. (CN) | 2025-10-08 | — | — | EP | disclosed |
| EP-3954685-B1 | SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | US HEALTH (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-0687266-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1995-12-20 | — | — | EP | disclosed |
| EP-0498184-B1 | Organic nonlinear optical material | MITSUBISHI CHEM CORP (JP) | 1995-10-18 | — | — | EP | disclosed |
| WO-1994020496-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1994-09-15 | — | — | WO | disclosed |
| US-5194511-A | Optical recording material, films and sheets | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1993-03-16 | — | — | US | disclosed |
| EP-0498184-A2 | Organic nonlinear optical material | MITSUBISHI CHEMICAL CORPORATION (JP) | 1992-08-12 | — | — | EP | disclosed |
| US-4118561-A | ANTIBACTERIAL, SYNERGISTIC, ANTI-CANCER ACTIVITY, ANTI-FOLIC ACID ACTIVITY | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-10-03 | — | — | US | disclosed |
| US-3956395-A | Distyrylbenzene disulfone derivatives | MEYER HANS RUDOLF | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230061859-A1 | PYRIDO[2,3-D]PYRIMIDINE HIV-1 REVERSE TRANSCRIPTASE INHIBITOR WB3, PREPARATION METHOD AND APPLICATION THEREOF | TYMP, CDK3, TYMS | ENPP2 2429/4885PTGS2 2846/4885KCNJ1 3341/4885 |
| US-10590145-B2 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | TYMP, DPYD, TPMT | ENPP2 1619/4885PTGS2 792/4885KCNJ1 2230/4885 |
| US-20260035361-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | ELAVL1, ELAVL3, HNRNPL | ENPP2 2490/4885PTGS2 4197/4885KCNJ1 3666/4885 |
| US-20200031844-A1 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | TYMP, DPYD, TPMT | ENPP2 1619/4885PTGS2 792/4885KCNJ1 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.